Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades Globus Medical to Neutral

BTIG Downgrades Globus Medical to Neutral

BTIG analyst Ryan Zimmerman downgrades Globus Medical (NYSE:GMED) from Buy to Neutral.

byBenzinga Newsdesk

February 10, 2023

1 minute read

BTIG analyst Ryan Zimmerman downgrades Globus Medical (NYSE:GMED) from Buy to Neutral.

Analyst Ratings

Key Takeaways From Tronox Holdings Analyst Ratings

By Benzinga Insights

January 11, 12:00 PM

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Tronox Holdings…

TROX

Analyst Ratings

Expert Ratings for Restaurant Brands Intl

By Benzinga Insights

March 31, 12:00 PM

Restaurant Brands Intl (NYSE:QSR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

QSR

HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Lowers Price Target to $9

By Benzinga Newsdesk

July 25, 6:25 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and lowers the price target from $11 to $9.

ETON

NVIDIA Sees Q4 2022 Revenue $6B Vs $6.09B Est

By Benzinga Newsdesk

November 16, 5:21 PM

NVIDIA's outlook for the fourth quarter of fiscal 2023 is as follows: Revenue is expected to be $6.00 billion, plus or minus 2%. GAAP and non-GAAP gross margins are expected to

NVDA

BTIG Downgrades Globus Medical to Neutral

Related Posts

Key Takeaways From Tronox Holdings Analyst Ratings

Expert Ratings for Restaurant Brands Intl

HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Lowers Price Target to $9

NVIDIA Sees Q4 2022 Revenue $6B Vs $6.09B Est